Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Weighted Average and Diluted) (2020 - 2025)

Tarsus Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.19 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.19 for Q4 2025, up 67.8% from a year ago — trailing twelve months through Dec 2025 was -$1.61 (up 47.9% YoY), and the annual figure for FY2025 was -$1.59, up 48.21%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.19 at Tarsus Pharmaceuticals, up from -$0.3 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TARS hit a ceiling of $0.47 in Q1 2021 and a floor of -$1.28 in Q3 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.68 (2021), compared with a mean of -$0.63.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 163.51% in 2021 and later crashed 387.5% in 2023.
  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.72 in 2021, then soared by 31.94% to -$0.49 in 2022, then crashed by 159.18% to -$1.27 in 2023, then skyrocketed by 53.54% to -$0.59 in 2024, then skyrocketed by 67.8% to -$0.19 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.19 (Q4 2025), -$0.3 (Q3 2025), and -$0.48 (Q2 2025) per Business Quant data.